On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma

ConclusionThe on-treatment CRP-control could be the predictive factor for the efficacy of nivolumab in refractory mRCC patients.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research